Study design and vaccination
The phase 1 clinical trial of PIV5-RSV vaccine (BLB201; Primary outcome measures included (i) solicited AEs (days 1 to 8) and (ii) unsolicited AEs (days 1 to 29). Secondary outcome measures included (i) serum IgG titers to RSV protein (days 15 and 29), (ii) SAEs (days 1 to 181), and (iii) AEs of special interest (AESIs) including new onset chronic medical conditions and medically attended AEs (days 1 to181).